Your browser doesn't support javascript.
loading
Management of Heart Failure in a Resource-Limited Setting: Expert Opinion from India.
Jain, Peeyush; Guha, Santanu; Kumar, Soumitra; Sawhney, J P S; Sharma, Kamal; Sureshkumar, K P; Mehta, Ashwani; Dhediya, Rajnish; Gaurav, Kumar; Mittal, Rajan; Kotak, Bhavesh.
Afiliação
  • Jain P; Fortis Escorts Heart Institute, New Delhi, India.
  • Guha S; Medical College, Kolkata, India.
  • Kumar S; Fortis Hospital, Anandapur, Kolkata, India.
  • Sawhney JPS; Sir Ganga Ram Hospital, Delhi, India.
  • Sharma K; Apollo Hospitals, U N Mehta Institute of Cardiology, Ahmedabad, India.
  • Sureshkumar KP; Kauvery Hospital, Mylapore, Chennai, India.
  • Mehta A; Sir Ganga Ram Hospital, New Delhi, India.
  • Dhediya R; Dr Reddy's Laboratories Ltd, Hyderabad, Telangana, India. rajnishd@drreddys.com.
  • Gaurav K; Dr Reddy's Laboratories Ltd, Hyderabad, Telangana, India.
  • Mittal R; Dr Reddy's Laboratories Ltd, Hyderabad, Telangana, India.
  • Kotak B; Dr Reddy's Laboratories Ltd, Hyderabad, Telangana, India.
Cardiol Ther ; 13(2): 243-266, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38687432
ABSTRACT
Heart failure poses a global health challenge affecting millions of individuals, and access to guideline-directed medical therapy is often limited. This limitation is frequently attributed to factors such as drug availability, slow adoption, clinical inertia, and delayed diagnosis. Despite international recommendations promoting the use of guideline-directed medical therapy for heart failure management, personalized approaches are essential in settings with resource constraints. In India, crucial treatments like angiotensin II receptor blocker neprilysin inhibitors and sodium-glucose co-transporter 2 inhibitors are not fully utilized despite their established safety and efficacy. To address this issue, an expert consensus involving 150 specialists, including cardiologists, nephrologists, and endocrinologists, was convened. They deliberated on patient profiles, monitoring, and adverse side effects and provided tailored recommendations for guideline-directed medical therapy in heart failure management. Stressing the significance of early initiation of guideline-directed medical therapy in patients with heart failure, especially with sodium-glucose co-transporter 2 inhibitors, the consensus also explored innovative therapies like vericiguat. To improve heart failure outcomes in resource-limited settings, the experts proposed several measures, including enhanced patient education, cardiac rehabilitation, improved drug access, and reforms in healthcare policies.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cardiol Ther Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Índia

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cardiol Ther Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Índia